Close

Chr. Hansen Holding A/S - Interim report 1 September 2015 - 30 November 2015

 

Company announcement no.02/2016

“We experienced a strong start to 2015/16, and 14% organic revenue growth in Q1 underlines our unique position in markets within microbial and natural color solutions with attractive growth opportunities. We continue to implement our Nature’s No. 1 strategy, and I’m very pleased with the progress. We have signed an agreement to acquire Nutrition Physiology Company, which will expand our current activities in animal health, and we have entered into our first commercial partnership in the human microbiome initiative,” says CEO Cees de Jong.

“Profitability increased in Q1, not least due to the positive impact from the scalability of our production platform in cultures and enzymes. As a result, the EBIT margin before special items increased by 2 percentage points to 25.2%”.

“Based on the strong start to the year, we now expect organic revenue growth of 9-11% while the EBIT margin before special items is still expected to be above the 27.1% achieved in 2014/15.”

2015/16 IN BRIEF

Q1 results

Progress on Nature’s No. 1

OUTLOOK FOR 2015/16                                                 

The outlook for 2015/16 has been adjusted compared to the announcement of 21 October 2015 (). The agreement to acquire Nutrition Physiology Company is not impacting the outlook.

Organic revenue growth: 9-11% (previously 8-10%)

Research & development expenditures incurred (% of revenue): 6.5-7.0% (previously 6.5-7.0%)

EBIT margin before special items: above 2014/15 (previously above 2014/15)

Free cash flow before acquisitions, divestments and special items: above 2014/15 (previously above 2014/15

 

For further information, please contact:

Anders Mohr Christensen, Senior Director, Investor Relations
Tel: +45 4574 7618

Klara Halkjaer, Head of media relations

Tel: +45 4574 7474

 

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2014/15 financial year was EUR 859 million. The company has more than 2,600 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen. For further information, please visit www.chr-hansen.com.

Attachments

_No 02 2016 US.pdf
Appendix_No 01 2016 US.pdf